<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088059</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1559-HNCG</org_study_id>
    <secondary_id>2017-000086-74</secondary_id>
    <nct_id>NCT03088059</nct_id>
  </id_info>
  <brief_title>Biomarker-based Study in R/M SCCHN</brief_title>
  <acronym>UPSTREAM</acronym>
  <official_title>A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomarker-driven trial that will enroll patients with recurrent or metastatic
      squamous cell carcinoma of the head and neck progressing after first-line platinum-based
      chemotherapy. Based on potential biomarkers and molecular alterations identified in the
      biopsy from the central platform, patients will be allocated in different cohorts. There will
      be biomarker-positive patient cohorts and immunotherapy cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at week 16</measure>
    <time_frame>The Progression Free Survival Rate (PFSR) analysis will be performed at week 16 for each patient in cohorts 1, 2 and 3.</time_frame>
    <description>Progression Free Survival Rate (PFSR) at week 16 will be assessed as primary endpoint for all patients from cohorts 1, 2 and 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response Rate (ORR) at month 6</measure>
    <time_frame>Objective response Rate (ORR) at month 6 will be performed at month 6 for each patient in cohort 4.</time_frame>
    <description>Objective response Rate (ORR) at month 6 will be assessed as primary endpoint for all patients from cohort 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 months after first patient in</time_frame>
    <description>Objective Response Rate will be measured according to both RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according CTCAE version 4.03</measure>
    <time_frame>54 months after first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients included in each patient cohort according the biomarker testing</measure>
    <time_frame>42 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with an evaluable fresh tumor biopsy</measure>
    <time_frame>42 months after first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Patient Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib 40 mg given orally, once daily, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort 1</arm_group_label>
    <arm_group_label>Patient Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)</description>
    <arm_group_label>Patient Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care</description>
    <arm_group_label>Patient Cohort 1</arm_group_label>
    <arm_group_label>Patient Cohort 2</arm_group_label>
    <arm_group_label>Patient Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2201</intervention_name>
    <description>Monalizumab given via intravenous injection, 10mg/kg, every 2 weeks</description>
    <arm_group_label>Patient Cohort 4</arm_group_label>
    <other_name>Monalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Histologically confirmed recurrent and/or metastatic SCCHN of the oral cavity,
             oropharynx, hypopharynx or larynx not amenable to curative treatment.

          -  At least one measurable lesion by MRI or CT-scan according to RECIST 1.1, evaluated
             within 3 weeks prior to treatment allocation. Such lesion must not have been
             previously irradiated; if the measurable lesion(s) have been irradiated, clear
             progression must be documented.

          -  Progressive disease after first line platinum-based chemotherapy with or without
             cetuximab given as palliative treatment or progressive disease within 1 year if
             platinum-based chemotherapy was given as a part of the multimodal curative treatment.

          -  ECOG performance status 0 -1.

          -  Tumor core biopsy from any accessible tumor site available for central testing.

          -  Patients must have adequate organ function, evaluated within 14 days prior to
             treatment allocation.

          -  Patients ≥ 18 years old and must be able to give written informed consent.

          -  Patients ≥ 70 years old must undergo the G8 screening.

          -  Women of child-bearing potential must have a negative pregnancy test (serum or urine
             within the 72 hours prior to cohort allocation).

          -  Sexually active patients must use highly effective methods of contraception as of
             registration and up to 6 months after the last treatment dose.

          -  Female subjects who are breast feeding should discontinue nursing prior to the first
             dose of study treatment and up to 6 months after the last study treatment.

          -  Before patient registration/randomization, written informed consent must be given
             according to ICH/GCP, and national/local regulations.

        General Exclusion Criteria:

          -  Unresolved and significant toxicity CTCAE version 4.03 grade ≥ 2 from previous
             anticancer therapy other than alopecia.

          -  Any of the following within 6 months prior to treatment allocation: myocardial
             infarction, severe/unstable angina, ongoing cardiac dysrhythmias of CTCAE version 4.03
             Grade 2 or more, atrial fibrillation of any grade, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure or ejection fraction of less than 50%,
             cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary
             embolism. Significant active cardiac disease including uncontrolled high blood
             pressure according to the CTCAE version 4.03 grade 3.

          -  Nasopharynx and sino-nasal tumor.

          -  Surgery or investigational drugs or chemotherapy or other anticancer therapy within 4
             weeks before treatment allocation. Curative radiation therapy (60-70 Gy) within 8
             weeks of treatment allocation. Palliative radiation therapy (e.g. 8 Gy on a painful
             lesion) will be allowed.

          -  Known untreated and uncontrolled brain metastases or carcinomatous meningitis.

          -  Known diagnosis of immune deficiency or a known history of Human Immunodeficiency
             Virus (HIV) (HIV 1/2 antibodies).

          -  Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected) or pre-existing liver cirrhosis.

          -  Known pre-existing interstitial lung disease (ILD). Bronchoemphysema should not be
             considered as ILD.

          -  Other uncontrolled active illnesses (active infections requiring antibiotics, bleeding
             disorders, uncontrolled diabetes, …).

          -  Any psychiatric, psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Any malignancy (other than SCCHN, non-melanoma skin cancer or localized cervical
             cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the
             skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to
             treatment allocation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominiek Staelens, PhD</last_name>
    <phone>+32 2 774 15 34</phone>
    <email>dominiek.staelens@eortc.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study e-mail address</last_name>
    <email>1559@eortc.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital De Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen - Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne - UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois-Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

